SOLV vs ABT vs RMD Stock Comparison

Solventum, Abbott Laboratories and Resmed Prices as of Nov 13, 2026 Peers: Industry group
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.22B
P/E
97.6x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
2 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.94B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
3 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.50B
P/E
21.7x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

11 decided of 12

Resmed leads on 6 of the 12 questions below (Resmed 6, Abbott Laboratories 3, Solventum 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSOLVABTRMDLeader
Larger companyMarket capitalisation $15.22B $187.94B $34.50B ABT
Cheaper on earningsLower P/E, profitable companies only 97.6x 40.0x 21.7x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.8x 19.1x 18.5x SOLV
Faster revenue growthRevenue growth, trailing twelve months -2.8% +10.0% +9.0% ABT
More profitableNet margin, trailing twelve months 1.9% 9.7% 27.8% RMD
Better return on capitalReturn on invested capital 4.2% 5.7% 22.0% RMD
Less leveragedLower net debt / EBITDA 4.7x 2.5x -0.3x RMD
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +18.4% -16.0% -5.0% SOLV
Better 5-year returnAnnualised price return, 5 years — -3.3%/yr -1.2%/yr RMD
Less volatileAnnualised volatility, 1 year 30.1% 28.5% 31.1% ABT
Higher overall scoreMean of the five percentile scores vs peers 51/100 56/100 80/100 RMD

Percentile Scorecard

SOLVABTRMD

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSOLVABTRMD
Valuation 70 #74 of 243 74 #65 of 243 75 #62 of 243
Growth 3 #221 of 228 26 #168 of 228 60 #92 of 228
Profitability 71 #66 of 222 82 #41 of 222 99 #3 of 222
Financial Health 15 #210 of 248 33 #167 of 248 76 #61 of 248
Shareholder Returns 94 #10 of 158 65 #56 of 158 89 #18 of 158
Overall 51 56 80
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSOLVABTRMDSPY
1 month +2.0%+5.4%+1.7% -2.0%
3 months +0.5%-2.4%+6.7% -2.8%
6 months +19.9%+28.5%+18.6% +2.0%
Year to date +12.4%-13.4%-0.6% +10.6%
1 year +18.4%-16.0%-5.0% +12.2%
3 years —+11.8%+62.6% +68.1%
3 years, per year —+3.8%+17.6% +18.9%
5 years —-15.5%-6.0% +61.4%
5 years, per year —-3.3%-1.2% +10.1%
10 years —+170.4%+300.2% +248.5%
10 years, per year —+10.5%+14.9% +13.3%

Risk

MeasureSOLVABTRMDSPY
Volatility, 1Y 30.1%28.5%31.1% 13.6%
Downside volatility, 1Y 29.3%27.8%33.9% 13.9%
Beta vs S&P 500, 1Y 0.610.070.51 1.00
Return / volatility, 1Y 0.61-0.56-0.16 0.90
Max drawdown, 5Y -40.0%-41.6%-49.8% -25.4%
From 52-week high -3.7%-16.9%-13.2% -3.2%
52-week high $92.45$130.59$275.96 $779.14
52-week low $62.49$82.56$182.82 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSOLVABTRMD
P/E now vs peer median 97.5xmedian 26.5x 40.0xmedian 26.5x 21.5xmedian 26.5x
P/S now vs peer median 1.9xmedian 2.7x 3.9xmedian 2.7x 5.9xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 20.3xmedian 18.4x 15.8xmedian 18.4x
P/FCF now vs peer median 156.0xmedian 25.4x 27.8xmedian 25.4x 20.9xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 3.6xmedian 2.5x 5.7xmedian 2.5x
PEG now vs peer median —median 0.98 -13.92median 0.98 0.99median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSOLVABTRMD
Revenue $8.16B $48.23B $5.73B
Gross profit $4.47B $27.46B $3.50B
Operating income $454.00M $6.65B $1.89B
Net income $156.00M $4.70B $1.59B
Free cash flow – $6.76B $1.61B
R&D $723.00M $3.31B $393.82M
EPS (diluted) $0.91 $2.70 $11.11
Cash & equivalents $451.00M $4.05B $1.01B
Total debt $5.07B $31.16B $409.60M
Shares (diluted) 170.80M 1.74B 143.41M
Enterprise value $12.93B $161.80B $28.94B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSOLVABTRMD
P/E 97.5x 40.0x 21.5x
P/FCF 156.0x 27.8x 20.9x
P/Operating cash flow 48.8x 21.2x 19.0x
P/S 1.9x 3.9x 5.9x
P/B 3.1x 3.6x 5.7x
P/Tangible book 6.1x 5.9x 6.1x
EV/EBITDA 20.3x 20.3x 15.8x
EV/EBIT 43.5x 32.3x 17.5x
EV/Revenue 2.4x 4.5x 5.8x
EV/FCF – 31.8x 20.6x
EV/Operating cash flow 63.7x 24.3x 18.7x
PEG (3Y EPS CAGR) – -13.92 0.99

Growth

14 metrics
MetricSOLVABTRMD
Revenue growth (1Y) -2.8% 10.0% 9.0%
Revenue CAGR (3Y) – 6.5% 9.4%
Gross profit growth (1Y) -1.6% 12.1% 11.0%
Gross profit CAGR (3Y) – 7.8% 13.2%
Operating income growth (1Y) -79.3% -13.8% 8.5%
Operating income CAGR (3Y) – 3.5% 18.2%
Net income growth (1Y) -89.8% -66.4% 10.8%
Net income CAGR (3Y) – -3.1% 20.7%
EPS growth (1Y) -89.5% -66.1% 13.5%
EPS CAGR (3Y) – -2.9% 21.8%
Operating cash flow growth (1Y) -37.1% -2.9% -6.0%
Operating cash flow CAGR (3Y) – 10.6% 23.7%
Free cash flow growth (1Y) – -2.3% -9.0%
Free cash flow CAGR (3Y) – 14.6% 25.5%

Profitability

14 metrics
MetricSOLVABTRMD
Gross margin 54.8% 56.9% 61.1%
EBITDA margin 11.9% 21.9% 36.4%
Operating margin 5.6% 13.8% 33.0%
Pretax margin 2.1% 13.6% 35.1%
Net margin 1.9% 9.7% 27.8%
FCF margin – 14.0% 28.1%
Operating cash flow margin 3.8% 18.4% 30.9%
Return on equity 3.3% 9.1% 25.4%
Return on assets 1.1% 4.3% 18.5%
Return on invested capital 4.2% 5.7% 22.0%
Return on capital employed 4.3% 7.2% 26.1%
Asset turnover 0.6x 0.4x 0.7x
Cash conversion (OCF / net income) 2.0x 1.9x 1.1x
Stock comp / revenue 2.1% 1.5% 2.0%

Financial Health

11 metrics
MetricSOLVABTRMD
Debt / assets 35.8% 28.8% 5.0%
Debt / equity 1.1x 0.6x 0.1x
Net debt / EBITDA 4.7x 2.5x -0.3x
Debt / FCF – 4.6x 0.3x
Liabilities / assets 66.1% 52.3% 27.6%
Equity / assets 33.9% 47.7% 72.4%
Interest coverage – 6.7x 81.1x
Current ratio 1.0x 1.5x 2.6x
Quick ratio 0.5x 0.8x 1.5x
Cash ratio 0.1x 0.3x 0.8x
Altman Z-score 1.85 3.36 12.00

Shareholder Returns

7 metrics
MetricSOLVABTRMD
Dividend yield – 2.3% 1.1%
Net buyback yield 2.7% 0.7% 4.2%
Shareholder yield 2.7% 3.0% 5.3%
Payout ratio (earnings) – 92.0% –
Payout ratio (FCF) – 64.0% –
Dividend growth (1Y) – 6.9% –
Dividend CAGR (3Y) – 7.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSOLVABTRMD
Forward P/E 12.8xFY2026 19.1xFY2026 18.5xFY2027
EPS, next fiscal year $6.93FY2026 $5.69FY2026 $12.92FY2027
EPS growth, next FY +13.4%FY2026 +10.5%FY2026 +15.7%FY2027
EPS growth, the year after +15.3% +10.2% +8.9%
Revenue, next fiscal year $7.71BFY2026 $52.99BFY2026 $5.99BFY2027
Revenue growth, next FY -7.3%FY2026 +19.5%FY2026 +6.0%FY2027
Revenue growth, the year after +5.8% -2.3% -3.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSOLVABTRMD
Held by institutions 73.9% 79.2% 68.7%
Institutions holding 882 2,983 889
Change in shares held, QoQ -0.9% +0.3% +3.2%
Institutions buying 370 1,261 404
Institutions selling 286 1,379 360
Buyers to sellers 1.29 0.91 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SOLVABTRMD
SOLV 1.00 0.37 0.45
ABT 0.37 1.00 0.41
RMD 0.45 0.41 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SOLV, ABT and RMD?

Abbott Laboratories (ABT) is the largest by market capitalisation: Solventum (SOLV) $15.22B, Abbott Laboratories (ABT) $187.94B, Resmed (RMD) $34.50B.

Which stock is cheaper, SOLV, ABT and RMD?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Solventum (SOLV) 97.6x, Abbott Laboratories (ABT) 40.0x, Resmed (RMD) 21.7x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Solventum (SOLV) 12.8x, Abbott Laboratories (ABT) 19.1x, Resmed (RMD) 18.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Solventum (SOLV) -2.8%, Abbott Laboratories (ABT) +10.0%, Resmed (RMD) +9.0%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Solventum (SOLV) 1.9%, Abbott Laboratories (ABT) 9.7%, Resmed (RMD) 27.8%). On return on invested capital, Resmed (RMD) leads (Solventum (SOLV) 4.2%, Abbott Laboratories (ABT) 5.7%, Resmed (RMD) 22.0%).

Which stock has performed better?

Over the past year Solventum (SOLV) returned the most: Solventum (SOLV) +18.4%, Abbott Laboratories (ABT) -16.0%, Resmed (RMD) -5.0%. Over five years, Resmed (RMD) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Resmed (RMD) -1.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Solventum (SOLV) 0.00%, Abbott Laboratories (ABT) 0.02%, Resmed (RMD) 0.00%. Solventum (SOLV) and Resmed (RMD) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Solventum (SOLV) 30.1%, Abbott Laboratories (ABT) 28.5%, Resmed (RMD) 31.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SOLV, ABT and RMD?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.